Theresa Boni - 01 Apr 2022 Form 4 Insider Report for Surface Oncology, Inc.

Reporting relationship: General Counsel & Secretary
Issuer ticker: N/A
Reported as of: 01 Apr 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Apr 2022, 20:00:25 UTC
Prior SEC filing: 18 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Robert Ross, as Attorney-in-Fact

Key filing fact

Theresa Boni filed Form 4 for Surface Oncology, Inc. on 01 Apr 2022.

Key facts

This page summarizes Theresa Boni's Form 4 filing for Surface Oncology, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 01 Apr 2022, 20:00.

Change

Previous filing in this sequence was filed on 18 Mar 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SURF transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +120,000
Change %
Price: $0.000000
Shares after: 120,000
Date: 01 Apr 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 120,000
Exercise price: $2.87
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the Options shall vest on March 14, 2023, and the remainder of the Options shall vest in equal monthly installments over the following three-year period, such that all of the Options shall be vested on March 14, 2026, subject to the Reporting Person's continued service relationship with the Company on each such vesting date.